1. Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency.
The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. A separate experiment was performed as described in Fig. 2A. At the end of treatment, BM cells from each group (1 × 106, 0.5 × 106, and 0.25 × 106 cells per mouse) plus 0.2 × 106 wild-type BM cells were transplanted into wild-type FBV/N recipient mice irradiated at 900 cGy (Fig. 2A; arm III). (A) PB leukemia burden at the end of treatments. (B) GFP+ PB cells obtained from mice 16 weeks after secondary transplant at 0.25 × 106 cells per mouse (left, plotted as mean ± SEM; right, individual animals). (C) PB engrafted/total transplanted mice and LT-HSC frequency in mice transplanted with BM cells from each treatment group. (D) BM GFP+ cells and Bcr-Abl mRNA expression in BM cells in mice 16 weeks after secondary transplant at 0.25 × 106 cells per mouse.
Bing Z. Carter et al., Sci Transl Med 2016;8:355ra117
Copyright © 2016, American Association for the Advancement of Science